Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events

被引：18

作者：

Takai, Ryo ^{[1
,2
]}

Funakoshi, Yohei ^{[2
,3
]}

Suto, Hirotaka ^{[2
,3
]}

Nagatani, Yoshiaki ^{[2
,3
]}

Imamura, Yoshinori ^{[2
,3
]}

Toyoda, Masanori ^{[2
,3
]}

Yakushijin, Kimikazu ^{[2
,3
]}

Kiyota, Naomi ^{[2
,3
,4
]}

Harada, Ken-Ichi ^{[2
,5
]}

Yamashita, Kimihiro ^{[1
,2
]}

Kakeji, Yoshihiro ^{[1
,2
]}

Minami, Hironobu ^{[2
,3
,4
]}

机构：

[1] Kobe Univ Hosp, Dept Surg, Div Gastrointestinal Surg, Kobe, Hyogo, Japan

[2] Grad Sch Med, Kobe, Hyogo, Japan

[3] Kobe Univ Hosp, Dept Med, Div Med Oncol Hematol, Kobe, Hyogo, Japan

[4] Kobe Univ Hosp, Canc Ctr, Kobe, Hyogo, Japan

[5] Kobe Univ Hosp, Dept Surg, Div Urol, Kobe, Hyogo, Japan

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 02期

关键词：

Immune checkpoint inhibitor; immune-related adverse event; serum soluble interleukin-2 receptor; CANCER; BLOCKADE; RECEPTOR; LEVEL;

D O I：

10.21873/anticanres.14857

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor ( sIL-2R). Patients and Methods: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. Results: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade >= 2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. Conclusion: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.

引用

页码：1021 / 1026

页数：6

共 21 条

[1] Serum soluble interleukin 2 receptor in human cancer of adults and children: a review [J].

Bien, E. ;

Balcerska, A. .

BIOMARKERS, 2008, 13 (01) :1-26

[2] PROLONGED ELEVATIONS OF SOLUBLE INTERLEUKIN-2 RECEPTORS IN TUBERCULOSIS [J].

BROWN, AE ;

RIEDER, KT ;

WEBSTER, HK .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (04) :1036-1038

[3] Immune dysregulation in cancer patients developing immune-related adverse events [J].

Khan, Shaheen ;

Khan, Saad A. ;

Luo, Xin ;

Fattah, Farjana J. ;

Saltarski, Jessica ;

Gloria-McCutchen, Yvonne ;

Lu, Rong ;

Xie, Yang ;

Li, Quan ;

Wakeland, Edward ;

Gerber, David E. .

BRITISH JOURNAL OF CANCER, 2019, 120 (01) :63-68

[4] Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review [J].

Khoja, L. ;

Day, D. ;

Chen, T. Wei-Wu ;

Siu, L. L. ;

Hansen, A. R. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2377-2385

[5] Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events [J].

Nakamura, Yoshiyuki .

FRONTIERS IN MEDICINE, 2019, 6 :1-18

[6] CLINICAL-SIGNIFICANCE OF SOLUBLE INTERLEUKIN-2 RECEPTOR FOR MONITORING THE DISEASES ASSOCIATED WITH ACTIVATED LYMPHOCYTES AND VIRAL-INFECTIONS [J].

OBARA, T ;

VODIAN, MA ;

KUNG, PC .

JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1992, 6 (06) :423-436

[7] The blockade of immune checkpoints in cancer immunotherapy [J].

Pardoll, Drew M. .

NATURE REVIEWS CANCER, 2012, 12 (04) :252-264

[8]

Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]

[9] Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group [J].

Puzanov, I. ;

Diab, A. ;

Abdallah, K. ;

Bingham, C. O., III ;

Brogdon, C. ;

Dadu, R. ;

Hamad, L. ;

Kim, S. ;

Lacouture, M. E. ;

LeBoeuf, N. R. ;

Lenihan, D. ;

Onofrei, C. ;

Shannon, V. ;

Sharma, R. ;

Silk, A. W. ;

Skondra, D. ;

Suarez-Almazor, M. E. ;

Wang, Y. ;

Wiley, K. ;

Kaufman, H. L. ;

Ernstoff, M. S. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[10] THE SOLUBLE INTERLEUKIN-2 RECEPTOR - BIOLOGY, FUNCTION, AND CLINICAL-APPLICATION [J].

RUBIN, LA ;

NELSON, DL .

ANNALS OF INTERNAL MEDICINE, 1990, 113 (08) :619-627

← 1 2 3 →